Product Information
CYCLOSET 0.8 MG TABLET is a brand product labeled by Avvisto Therapeutics LLC, priced at $5.2563 per EA under NDC 73515012330. Its NADAC has been published 93 times since Dec 25, 2024.
FDA first approved this application on May 5, 2009.
Strength
.8 mg/1
Manufacturer
Avvisto Therapeutics LLCNDC
73515012330
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BROMOCRIPTINE MESYLATEApproval Type
New Drug (NDA)
FDA Application
NDA020866FDA Approved
5/5/2009
On Market Since
5/23/2024
Pharmacological Classes
Price Statistics
The NADAC for CYCLOSET 0.8 MG TABLET has been published 93 times since Dec 25, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.2563 per EA |
|---|---|
| All-time high | $5.3153 (Jul 16, 2025) |
| All-time low | $5.2519 (Nov 19, 2025) |
| 52-week high | $5.2580 |
| 52-week low | $5.2519 |
| Median price | $5.2563 |
| Average price | $5.2704 |
| Largest weekly change | +0.6% (May 21, 2025) |
| Weeks tracked | 93 |
| Tracking since | Dec 25, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the bromocriptine mesylate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Avvisto Therapeutics LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bromocriptine mesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Ergot Derivative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CYCLOSET 0.8 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CYCLOSET 0.8 MG TABLET, manufactured by Avvisto Therapeutics LLC, is $5.2563 per EA (NDC 73515012330), effective Sep 30, 2026.
How has the price of CYCLOSET 0.8 MG TABLET changed over time?
Over the history we have for it, the NADAC for CYCLOSET 0.8 MG TABLET has held within roughly two percent of its current level. It has been tracked across 93 weekly CMS publications since Dec 25, 2024.
What are the highest and lowest recorded NADAC prices for CYCLOSET 0.8 MG TABLET?
Since Dec 25, 2024, the NADAC for CYCLOSET 0.8 MG TABLET has ranged from a low of $5.2519 (Nov 19, 2025) to a high of $5.3153 (Jul 16, 2025), with a median of $5.2563 per EA.
Are there cheaper alternatives to CYCLOSET 0.8 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of CYCLOSET 0.8 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CYCLOSET 0.8 MG TABLET?
CYCLOSET 0.8 MG TABLET (NDC 73515012330) is labeled by Avvisto Therapeutics LLC, and CMS classifies it as a brand product.